Biotechnology company.
2 AI-extracted insights from 1 source — podcasts, YouTube channels, and X/Twitter accounts.
Not enough scored insights about Equillium, Inc. in the last 30 days yet.
The 1 sources with the most insights about Equillium, Inc. on Kazuha.
AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.
The speaker is bullish, noting the stock 'rally's like crazy' and that they still own shares, suggesting a belief it may continue to perform well.
A new long position based on a high-risk, high-reward thesis. The speaker believes if the company's drug works, the stock could see a 20x-30x return, arbitraging the valuation gap with comparable companies.
The speaker is bullish, noting the stock 'rally's like crazy' and that they still own shares, suggesting a belief it may continue to perform well.
A new long position based on a high-risk, high-reward thesis. The speaker believes if the company's drug works, the stock could see a 20x-30x return, arbitraging the valuation gap with comparable companies.
Other assets that creators frequently mention in the same content as Equillium, Inc..
The most active sources covering Equillium, Inc. (EQ) on Kazuha are @realmartinshkreli. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.
Kazuha has indexed 2 AI-extracted insights about Equillium, Inc. (EQ) from 1 different source. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.
Creators covering Equillium, Inc. (EQ) most frequently also discuss ABVX, ATYR, AVSL, RKT, IONQ. See the "Discussed alongside" section above for full asset pages.